{"nctId":"NCT01680341","briefTitle":"Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine","startDateStruct":{"date":"2012-08-31","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":272,"armGroups":[{"label":"IDegAsp Simple","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/insulin aspart"]},{"label":"IDegAsp Step wise","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/insulin aspart"]}],"interventions":[{"name":"insulin degludec/insulin aspart","otherNames":["IDegAsp"]},{"name":"insulin degludec/insulin aspart","otherNames":["IDegAsp"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes (diagnosed clinically) for at least 24 weeks prior to Visit 2 (randomisation)\n* Currently treated with IGlar (Insulin Glargine) and up to 3 oral antidiabetic drugs (OADs) (metformin, DPP-4 inhibitor, sulphonylurea/glinide or alpha-glucosidase inhibitor). All antidiabetic treatments should have been ongoing for at least 12 weeks prior to Visit 2 (randomisation) and doses should have been stable in this period of time\n* Glycosylated haemoglobin (HbA1c) 7.0-10.0% (both inclusive) by central laboratory analysis\n* Body mass index (BMI) below or equal to 40 kg/m\\^2\n\nExclusion Criteria:\n\n* Treatment with glucagon-like peptide 1 (GLP-1) receptor agonists or thiazolidinediones (TZDs) both within the last 12 weeks prior to Visit 2 (randomisation)\n* Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty; all within the last 24 weeks prior to Visit 2 (randomisation)\n* Uncontrolled or untreated severe hypertension defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg\n* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during last 12 months) or hypoglycaemic unawareness as judged by the investigator\n* Life-threatening disease (e.g. cancer)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in HbA1c (Glycosylated Haemoglobin) (%)","description":"Change from baseline in HbA1c after 26 weeks of treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.45","spread":"0.09"},{"groupId":"OG001","value":"-1.33","spread":"0.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG)","description":"Change from baseline in fasting plasma glucose (FPG) after 26 weeks of treatment","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.68","spread":"0.23"},{"groupId":"OG001","value":"-1.98","spread":"0.23"}]}]}]},{"type":"SECONDARY","title":"Subjects With HbA1c Below 7.0%","description":"Number of subjects with HbA1c below 7% after 26 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"85","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects With HbA1c Below 7.0% Without Confirmed Hypoglycaemia","description":"Percentage of subjects with HbA1c below 7% without confirmed hypoglycaemic episodes after 26 weeks of treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.4","spread":null},{"groupId":"OG001","value":"32.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Treatment Emergent Adverse Events (TEAEs)","description":"A Treatment Emergent Adverse Event (TEAE) was defined as an event that had onset date on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"242","spread":null},{"groupId":"OG001","value":"286","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Confirmed Hypoglycaemic Episodes","description":"Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"552","spread":null},{"groupId":"OG001","value":"323","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Confirmed Hypoglycaemic Episodes in the Maintenance Period","description":"Confirmed hypoglycaemic episodes in the maintenance period (from Week 16 to the end of the trial including follow-up \\[Week 27\\]) consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Nocturnal (00:01-05:59) Confirmed Hypoglycaemic Episodes","description":"Confirmed hypoglycaemic episodes consisted of episodes of severe hypoglycaemia and minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 am.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":7,"n":135},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Influenza","Headache","Back pain"]}}}